Detalhe da pesquisa
1.
Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity.
Methods Mol Biol
; 2058: 261-270, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31486044
2.
A dynamic COVID-19 immune signature includes associations with poor prognosis.
Nat Med
; 26(10): 1623-1635, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32807934
3.
Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis.
Nat Med
; 26(12): 1951, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33247289
4.
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
J Immunother Cancer
; 7(1): 320, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753017
5.
Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
Macromol Biosci
; 18(1)2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28902983
6.
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.
Cancer Res
; 78(24): 6852-6865, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30449733
7.
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
EMBO Mol Med
; 9(8): 1067-1087, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28634161